logo-loader
viewCannPal Animal Therapeutics Ltd

CannPal Animal Therapeutics granted medical cannabis permit

The company listed on the ASX in October 2017 after raising $6M.

a dog sitting in a garden
Clinical trials planned for Q1 CY18.

CannPal Animal Therapeutics Ltd (ASX:CP1) has been granted an authorisation to possess and supply cannabis for scientific research by the New South Wales Ministry of Health.

The authorisation has been issued under the provisions of the Drug Misuse and Trafficking Act 1985.

Importantly, the permit allows CannPal to apply for permits to import cannabis for the clinical trials planned for Q1 CY18.

CannPal is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals.

The company listed on the ASX in October 2017 after raising $6 million at an issue price of $0.20 per share.

CannPal has been working closely with Invetus, Australasia’s largest veterinary research organisation, to facilitate the importation of cannabis for scientific research in companion animals.

CannPal’s agreement with Invetus allows the company to store and research its prohibited substances at a secure purpose-built animal health research facility.

The cannabis oils being imported are for the company’s pharmacokinetic and safety studies scheduled for Q1 CY18.

The University of Queensland will be providing bioanalytical services for the studies with the results anticipated in Q2 CY18.

Quick facts: CannPal Animal Therapeutics Ltd

Price: 0.13 AUD

ASX:CP1
Market: ASX
Market Cap: $12.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space. "The goal for the company is really to develop products that can address clear,...

on 25/6/18

2 min read